Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 604 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR The Switch of Breast Tumours to HER2-Low Status in Recurrence Might... May 8, 2021 Thank you! March 22, 2021 ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma Fatiga relacionada con el cáncer: Lo que las personas con cáncer... When You Have to Make Decisions for a Loved One With...
